Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.

Item
http://www.wikidata.org/entity/Q34620781
Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomasA gist of gastrointestinal stromal tumors: A review.Diagnosis and evaluation of gastric cancer by positron emission tomographyGEIS 2013 guidelines for gastrointestinal sarcomas (GIST)Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.Reintroduction of imatinib in GISTF-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors.Controversies in the management of gastrointestinal stromal tumors.The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest.Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases.A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
P2860

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.

Item
http://www.wikidata.org/entity/Q34620781
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@ast
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@en
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@nl
type
label
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@ast
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@en
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@nl
prefLabel
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@ast
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@en
Imatinib plus low-dose doxorub ...... roup for Research on Sarcomas.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Imatinib plus low-dose doxorub ...... Group for Research on Sarcomas
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698